Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Launched by FUDAN UNIVERSITY · Sep 9, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with locally advanced laryngeal and hypopharyngeal cancers, which are types of throat cancer. The study is looking at a combination of immunotherapy (a treatment that helps the immune system fight cancer) and chemotherapy, followed by either radiation therapy or organ-preserving surgery. The goal is to see how effective this treatment is and how it affects patients' quality of life compared to traditional treatments.

To be eligible for the trial, participants must be between 18 and 75 years old and have a confirmed diagnosis of laryngeal or hypopharyngeal cancer that can be surgically removed. They should have a measurable tumor and be in good overall health, with no recent serious infections or other major health issues. Participants can expect to receive the new treatment and be monitored closely for their response and side effects. This trial aims to find better treatment strategies that not only improve survival rates but also help maintain patients' quality of life.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signing of the informed consent form and willingness to comply with the study protocol.
• • 2. Age ≥18 and ≤75 years.
• • 3. Histologically confirmed laryngeal or hypopharyngeal squamous cell carcinoma.
• • 4. Locally advanced laryngeal/hypopharyngeal cancer patients eligible for surgical resection (AJCC 8th edition stage: T2N+M0, T3-T4aN0-3M0).
• • 5. Presence of at least one measurable lesion before treatment, in accordance with RECIST 1.1 criteria for "measurable lesions."
• • 6. Patients who have received neoadjuvant immunotherapy combined with chemotherapy and have achieved a partial response (PR) in the primary lesion according to RECIST 1.1 criteria and are suitable candidates for organ preservation surgery.
• • 7. Expected survival of more than 3 months.
• • 8. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
• 9. Good organ function, meeting the following criteria:
• • 1. Absolute neutrophil count (ANC) ≥1.5×10\^9/L.
• • 2. Platelet count ≥100×10\^9/L.
• • 3. Hemoglobin ≥9 g/dL.
• • 4. Serum albumin ≥2.8 g/dL.
• • 5. Total bilirubin ≤1.5× upper limit of normal (ULN), ALT, AST, and/or ALP ≤3× ULN.
• • 6. Serum creatinine ≤1.5× ULN and creatinine clearance ≥60 mL/min (Cockcroft-Gault formula, see Appendix III).
• • 7. Activated partial thromboplastin time (APTT) and international normalized ratio (INR) ≤1.5× ULN (patients on stable doses of anticoagulation with agents like low molecular weight heparin or warfarin, and INR within the expected therapeutic range, may be included).
• • 10. Patients with hepatitis B virus (HBV) infection, inactive/asymptomatic HBV carriers, or patients with chronic or active HBV infection with HBV DNA \<500 IU/mL (or 2500 copies/mL) at screening will be allowed to participate. Patients positive for hepatitis C antibodies, if HCV-RNA is negative at screening, will be allowed to participate.
• • 11. Females of childbearing potential must have a negative pregnancy test result in urine or serum ≤7 days before treatment initiation. They must use a medically accepted contraceptive measure (such as intrauterine device, oral contraceptives, or condoms) during the study treatment period, for at least 3 months after the last dose of toripalimab, and for at least 6 months after the last dose of chemotherapy.
• • 12. Non-sterilized male participants must be willing to use a medically accepted contraceptive measure (such as intrauterine device, oral contraceptives, or condoms) during the study treatment period, for at least 3 months after the last dose of toripalimab, and for at least 6 months after the last dose of chemotherapy.
• Exclusion Criteria:
• • 1. History of allergic reactions to any components of toripalimab, paclitaxel, or cisplatin.
• • 2. Pre-existing tracheostomy due to laryngeal dysfunction before treatment.
• • 3. History of or concurrent presence of other malignancies (except for those cured and with no cancer-related survival exceeding 5 years, such as basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid cancer). Patients with concurrent hypopharyngeal and esophageal cancers, where the lesions are not anatomically adjacent, will be diagnosed as having dual primary tumors and will not be eligible for inclusion.
• 4. Uncontrolled clinical cardiac symptoms or diseases, including:
• • 1. NYHA Class II or higher heart failure.
• • 2. Unstable angina.
• • 3. Myocardial infarction within the past year.
• • 4. Clinically significant ventricular or supraventricular arrhythmias requiring clinical intervention.
• 5. Previous treatment with any of the following:
• • 1. Use of any investigational drug within 4 weeks prior to the first dose of study treatment.
• • 2. Concurrent participation in another clinical trial, unless it is an observational (non-interventional) clinical trial.
• • 3. Requiring systemic treatment with corticosteroids (daily dose \>10 mg prednisone equivalent) or other immunosuppressive medications within 2 weeks prior to the first dose of study treatment, excluding corticosteroids for localized inflammation or prophylaxis against allergies or nausea/vomiting. Other specific circumstances should be discussed with the investigator. In the absence of active autoimmune disease, inhaled or topical steroids and adrenal replacement therapy with a dose of \>10 mg/day prednisone or equivalent are allowed.
• • 4. Vaccination with anti-tumor vaccines or administration of live vaccines within 4 weeks prior to the first dose of study treatment (for patients who received COVID-19 vaccine, a 2-week interval is required).
• • 5. Major surgery within 4 weeks before the first dose of study treatment or presence of severe trauma.
• • 6. Failure to recover to ≤ Grade 1 toxicity per CTCAE (except for alopecia and residual neuropathy related to prior platinum therapy) from previous cancer therapy or from any other cause unrelated to study/enrollment criteria.
• • 7. Experience of severe infections (CTCAE \> Grade 2) within 4 weeks before the first dose of study treatment, such as severe pneumonia requiring hospitalization, sepsis, or complicated infections. Baseline chest imaging indicating active pulmonary inflammation, presence of symptoms and signs of infection within 4 weeks before the first dose of study treatment, or requirement for oral or intravenous antibiotics to treat infection are exclusion criteria.
• • 8. Active autoimmune disease or history of autoimmune disease, such as interstitial lung disease, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, including but not limited to these diseases or syndromes. However, stable dose of thyroid replacement therapy for autoimmune-mediated hypothyroidism is allowed. Stable dose of insulin for type I diabetes is allowed. Patients with vitiligo or childhood-onset asthma/allergies requiring no intervention as adults are allowed.
• • 9. History of immune deficiency, including HIV positive test results, other acquired or congenital immunodeficiency diseases, or history of organ transplantation or allogeneic bone marrow transplantation.
• • 10. History of interstitial lung disease (excluding radiation pneumonitis not treated with steroids), non-infectious pneumonitis.
• • 11. Active tuberculosis infection found through medical history or CT scan, or presence of active tuberculosis infection within the past year prior to enrollment, or history of active tuberculosis infection more than 1 year ago but not formally treated.
• • 12. Presence of active hepatitis B (HBV DNA ≥500 IU/mL or 2500 copies/mL) or hepatitis C (HCV-RNA positive with HCV-RNA levels above the lower limit of detection of the assay) infection＊.
• • 13. Known history of substance abuse, alcohol abuse, or drug addiction.
• • 14. Pregnant or breastfeeding women.
• • 15. Other factors, as judged by the investigator, that may interfere with the participant's ability to comply with the study requirements or that may jeopardize the safety of the participant or the quality of the study data, including the presence of other severe diseases (including mental illness) requiring concurrent treatment, severe abnormal laboratory values, family or social factors, which might affect participant safety or data collection.
• • For participants who are HBsAg-positive and either HBV DNA-negative or with HBV DNA \<500 IU/mL or 2500 copies/mL, after receiving stable antiviral treatment, they may be included in this trial (treatment should be ongoing for \>2 weeks before enrollment, and continued for 6 months after the last dose of study treatment).